Shanghai Pharmaceuticals Holding Co Ltd banner

Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607

Watchlist Manager
Shanghai Pharmaceuticals Holding Co Ltd Logo
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Watchlist
Price: 16.93 CNY -0.35%
Market Cap: ¥62.8B

EV/S

0.3
Current
14%
Cheaper
vs 3-y average of 0.3

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
0.3
=
Enterprise Value
¥75.8B
/
Revenue
¥283.6B

Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.

EV/S
0.3
=
Enterprise Value
¥75.8B
/
Revenue
¥283.6B

Valuation Scenarios

Shanghai Pharmaceuticals Holding Co Ltd is trading below its 3-year average

If EV/S returns to its 3-Year Average (0.3), the stock would be worth ¥19.61 (16% upside from current price).

Statistics
Positive Scenarios
4/4
Maximum Downside
No Downside Scenarios
Maximum Upside
+1 332%
Average Upside
629%
Scenario EV/S Value Implied Price Upside/Downside
Current Multiple 0.3 ¥16.93
0%
3-Year Average 0.3 ¥19.61
+16%
5-Year Average 0.3 ¥19.81
+17%
Industry Average 3.8 ¥242.4
+1 332%
Country Average 3.3 ¥211.72
+1 151%

Forward EV/S
Today’s price vs future revenue

Today's Enterprise Value Revenue Forward EV/S
¥75.8B
/
Jan 2026
¥283.6B
=
0.3
Current
¥75.8B
/
Dec 2026
¥304.9B
=
0.2
Forward
¥75.8B
/
Dec 2027
¥322.2B
=
0.2
Forward
¥75.8B
/
Dec 2028
¥344.2B
=
0.2
Forward

Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.

Peer Comparison

All Multiples
EV/S
P/E
All Countries
Close

Market Distribution

Lower than 96% of companies in China
Percentile
4th
Based on 7 593 companies
4th percentile
0.3
Low
0 — 1.7
Typical Range
1.7 — 6.2
High
6.2 —
Distribution Statistics
China
Min 0
30th Percentile 1.7
Median 3.3
70th Percentile 6.2
Max 5 034 353.9

Shanghai Pharmaceuticals Holding Co Ltd
Glance View

Market Cap
62.8B CNY
Industry
Health Care

Shanghai Pharmaceuticals Holding Co Ltd, a giant in China's pharmaceutical industry, operates with a dual-engine strategy that seamlessly combines manufacturing and distribution. Established in the bustling metropolis of Shanghai, the company has swiftly become a cornerstone of China's healthcare landscape. Its manufacturing arm is a powerhouse of innovation and production, turning out a vast array of pharmaceutical products that encompass both traditional Chinese medicine and modern pharmaceuticals. These products range from patented medicines to essential generics, entering hospitals, clinics, and retail pharmacies nationwide, all the while feeding a robust supply chain that caters to the country's vast and diverse market needs. On the flip side, Shanghai Pharmaceuticals' extensive distribution network is the lifeline that ensures these vital medicines reach their destinations safely and efficiently. In an era where logistics and supply chain management are pivotal, the company excels through an advanced distribution system that connects manufacturers with end-users across China. This network is bolstered by strategic partnerships and a commitment to technological advancement, allowing the company to maintain agility and reliability in an ever-evolving market. Revenue streams flow not just from product sales but are heavily supplemented through strategic partnerships and services that enhance accessibility and affordability for healthcare providers and patients alike. As one of the top pharmaceutical firms in China, Shanghai Pharmaceuticals is adept at maneuvering the intricacies of healthcare demands, regulatory landscapes, and competitive dynamics, carving its niche as a leader in both innovation and distribution efficiency.

Intrinsic Value
45.61 CNY
Undervaluation 63%
Intrinsic Value
Price ¥16.93
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett